A Multicentre Double Blind Trial of Fluoxetine versus Amitriptyline in the Treatment of Depressive Illness

The antidepressant efficacy and side effect profile of a fixed dose of 20 mg/day of fluoxetine, a specific serotonin reuptake inhibitor, were compared to those of amitriptyline. Fifty-eight patients with DSM-III-R depression were randomly assigned to receive either fluoxetine or amitriptyline. Fifty-six patients (fluoxetine N = 23, amitriptyline N = 23) completed the 6 week study. Comparable antidepressant efficacy was demonstrated for the two drugs. Patients taking fluoxetine reported less side-effects than those taking amitriptyline.

Download Full-text

A Double Blind Trial of Moclobemide versus Amltrlptyllne in the Treatment of Depressive Disorders

Australian & New Zealand Journal of Psychiatry ◽

10.3109/00048679009062902 ◽

1990 ◽

Vol 24 (4) ◽

pp. 475-479 ◽

Cited By ~ 7

Author(s):

Gil M. Newburn ◽

Allen R. Fraser ◽

David B. Menkes ◽

Paul E. Mullen

Keyword(s):

Postural Hypotension ◽

Time Course ◽

Depressive Disorders ◽

Monoamine Oxidase Inhibitor ◽

Oxidase Inhibitor ◽

Side Effect Profile ◽

Double Blind Trial ◽

Double Blind ◽

Antidepressant Efficacy ◽

To Receive

The antidepressant efficacy and side-effect profile of amitriptyline were compared to those of moclobemide, a reversible monoamine oxidase inhibitor with selectivity for the type A isozyme. Forty nine patients with DSM-Ill major depression were randomly assigned to receive either amitriptyline or moclobemide. Thirty seven patients (amitriptyline n=l6, moclobemide n=21) completed the six week protocol, which was conducted under double blind conditions. The results indicated a comparable antidepressant time course and efficacy for the two treatments. Amitriptyline produced significantly more sedation and antimuscarinic side-eff ects. Moclobemide appears to be a well tolerated antidepressant without the liability to produce significant postural hypotension and without the need for a tyramine-poor diet.

Download Full-text

Management of relapsing/remitting multiple sclerosis with copolymer I (Copaxone)

Multiple Sclerosis Journal ◽

10.1177/135245859600100606 ◽

1996 ◽

Vol 1 (6) ◽

pp. 325-326 ◽

Cited By ~ 9

Author(s):

Kenneth P Johnson

Keyword(s):

Multiple Sclerosis ◽

Side Effects ◽

Regulatory Agencies ◽

Double Blind Trial ◽

Double Blind ◽

Relapsing Remitting ◽

European Regulatory ◽

Copolymer 1 ◽

Relapsing Remitting Multiple Sclerosis ◽

To Receive

Copolymer I (Copaxone) was evaluated in a multicenter, placebo-controlled, double-blind trial at 11 US universities. Two hundred and fifty-one relapsing-remitting ambulatory MS patients were randomized to receive 20 mg of copolymer 1 or placebo by daily subcutaneous injection for approximately 30 months. At conclusion, the copolymer 1 group had 32% fewer relapses (P=0.002) and significantly more were relapse-free (P=0.035). Significantly, more patients were receiving copolymer 1 had improved during the study, while more patients on placebo showed neurological decline (P=0.001). There were few side effects and no drug related laboratory abnormalities. Copolymer 1 is being considered by North American and European regulatory agencies for approval as a commercially available agent for the control of multiple sclerosis.

Download Full-text

Adrenocorticotropic hormone in the prevention of cisplatin-induced nausea and vomiting.

Journal of Clinical Oncology ◽

10.1200/jco.1983.1.10.635 ◽

1983 ◽

Vol 1 (10) ◽

pp. 635-639 ◽

Cited By ~ 7

Author(s):

N Colbert ◽

V Izrael ◽

J P Lotz ◽

D Stoppa-Lyonnet ◽

J M Vannetzel ◽

...

Keyword(s):

Side Effects ◽

Advanced Cancer ◽

Adrenocorticotropic Hormone ◽

Nausea And Vomiting ◽

Double Blind Trial ◽

Effective Agent ◽

Double Blind ◽

Blind Trial ◽

Long Acting ◽

To Receive

A double-blind trial to evaluate the antiemetic effects of adrenocorticotropic hormone (ACTH) in patients treated with cisplatin was performed. Thirty-seven adults with advanced cancer who were treated with cisplatin were randomly assigned to receive either synthetic long-acting ACTH (1 mg IM given 24 hours, 12 hours, and immediately preceding the administration of cisplatin) or a placebo given under the same conditions. All of the patients received chlorpromazine (50 mg IM) 30 minutes before cisplatin infusion. Patients receiving ACTH and chlorpromazine had significantly fewer episodes of vomiting (p less than 0.01) and shorter periods of nausea (p less than 0.02) than patients receiving placebo and chlorpromazine. Patients receiving ACTH and chlorpromazine were significantly more comfortable than patients receiving placebo and chlorpromazine. No important side effects were observed. ACTH may be an effective agent in preventing nausea and vomiting induced by cisplatin.

Download Full-text

Lithium Continuation Therapy Following Electroconvulsive Therapy

The British Journal of Psychiatry ◽

10.1192/bjp.139.4.284 ◽

1981 ◽

Vol 139 (4) ◽

pp. 284-287 ◽

Cited By ~ 51

Author(s):

A. Coppen ◽

M. T. Abou-Saleh ◽

P. Milln ◽

J. Bailey ◽

M. Metcalfe ◽

...

Keyword(s):

Electroconvulsive Therapy ◽

Depressive Illness ◽

High Rate ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial ◽

Clinical Recovery ◽

Continuation Therapy ◽

One Year ◽

To Receive

SummaryThirty-eight depressed patients who were treated with ECT were randomly assigned to receive lithium therapy or identical-looking placebo tablets for one year after clinical recovery in a double-blind trial. The patients who received placebo tablets spent an average of 7.8 weeks with an episode of depression (either as in-patients or day-patients) during the year. In comparison, patients who received lithium spent on average 1.7 weeks with an episode (P <0.02). The trial confirms the high rate of relapses after ECT and suggests that lithium considerably reduces this morbidity. It is suggested that ECT without continuation therapy is not a satisfactory treatment of depressive illness.

Download Full-text

A Double-Blind Controlled Trial of ‘Vivalan’ (Viloxazine Hydrochloride) and Imipramine Hydrochloride in the Treatment of Depression in General Practice

Journal of International Medical Research ◽

10.1177/030006057400200402 ◽

1974 ◽

Vol 2 (4) ◽

pp. 260-264 ◽

Cited By ~ 15

Author(s):

P F C Bayliss ◽

A R Dewsbury ◽

J F Donald ◽

J W Harcup ◽

M Mayer ◽

...

Keyword(s):

General Practice ◽

Side Effects ◽

General Practitioners ◽

Side Effect ◽

Controlled Trial ◽

Depressive Illness ◽

Double Blind ◽

Patient Study ◽

Treatment Of Depression ◽

Imipramine Hydrochloride

One hundred and twenty-three patients with mild to moderate depressive illness were entered into a double-blind between-patient study of viloxazine hydrochloride (150 mg/day, expressed as base) and imipramine hydrochloride (75 mg/day, expressed as salt) by nine general practitioners. Sixty-two took viloxazine and sixty-one took imipramine. Both drugs produced a statistically highly significant improvement in both the depressive and anxiety symptoms over the period of the study, an effect being seen as early as the seventh day of treatment. Viloxazine produced fewer side-effects than imipramine, in particular significantly less drowsiness and dry mouth. The only side-effect seen with viloxazine was an upper gastro-intestinal disturbance with nausea and occasional vomiting, but this was transient. It is concluded that viloxazine hydrochloride is an effective anti-depressant in mild to moderate cases of depression in general practice and has the advantage of fewer side-effects than imipramine. The absence of sedation with viloxazine is of particular value in the treatment of ambulant patients.

Download Full-text

Efficacy and Tolerance of Enteric-Coated Erythromycin Base (Ery-Max®) Administered Twice or Four Times Daily in Patients with Acute Bronchitis

Journal of International Medical Research ◽

10.1177/030006058301100506 ◽

1983 ◽

Vol 11 (5) ◽

pp. 285-288 ◽

Cited By ~ 2

Author(s):

Pehr-Samuel Pekkanen ◽

Kenneth Josefsson

Keyword(s):

Side Effects ◽

Clinical Effect ◽

Acute Bronchitis ◽

Response To Treatment ◽

Double Blind Trial ◽

Double Blind ◽

Erythromycin Base ◽

Enteric Coated ◽

New Formulation ◽

To Receive

We performed a double-blind trial of a new formulation of erythromycin base as enteric-coated pellets (Ery-Max®) in the treatment of acute bronchitis in 220 patients. Subjects were randomized to receive either 500 mg twice or 250 mgfour times a day for 10 days. The response to treatment as assessed clinically and by changes in sputum purulence was the same in the two groups. Thus 97% and 98% of the patients had a good or improved clinical effect. Treatment was well tolerated, but side-effects were encountered more often in the q.i.d. group (p > 0·05). In conclusion, the study showed that the enteric-coated erythromycin as pellets, given twice or four times daily for 10 days, was well tolerated and equally effective in acute bronchitis. Hence, the more convenient b.i.d. regimen can be recommended.

Download Full-text

Long-term efficacy and safety of imiquimod 5% and fluorouracil 1% creams in medical monotherapy of complex eyelid basal cell carcinomas

European Journal of Ophthalmology ◽

10.1177/11206721211035614 ◽

2021 ◽

pp. 112067212110356

Author(s):

Manpreet Singh ◽

Aditi Mehta Grewal ◽

Himanshi Singh ◽

Manjula Sharma ◽

Manpreet Kaur ◽

...

Keyword(s):

Basal Cell ◽

Side Effect ◽

The Elderly ◽

Fixed Dose ◽

Side Effect Profile ◽

Efficacy And Safety ◽

Term Efficacy ◽

Basal Cell Carcinomas ◽

Double Blinded

Purpose: To study the long-term efficacy and safety of local application of imiquimod 5% and fluorouracil 1% creams in complex eyelid basal cell carcinomas (BCCs). Methods: A retrospective, non-comparative study in biopsy-proven, complex (involving canthi or >50% of eyelid length) eyelid BCC patients who were medically unfit for surgical procedures. All patients were medically treated with either of the creams using fixed-dose regimens for a minimum of 3 months. All received oral vitamin C 500 mg QID for 3 months as an adjunct for collagen healing. A minimum of “post-treatment” follow-up of 12 months was observed. Results: Of total 30 patients, imiquimod 5% and fluorouracil 1% were used in 16 and 14 patients, respectively. The mean age of our patients was 70.5 years. The co-morbidities included – severe coronary artery disease using blood-thinners ( n = 19), poorly controlled diabetes ( n = 12), poorly controlled hypertension ( n = 6), on nebulization ( n = 3), and tuberculosis with pulmonary fibrosis ( n = 2). Complete clinical tumor resolution was noted in 10 and 8 patients over 12 and 16.5 weeks, respectively, in imiquimod and fluorouracil groups. Periocular skin erythema, chemical conjunctivitis, and skin depigmentation were seen in all the patients of imiquimod group. On the other hand, the local side-effect profile in fluorouracil patients was limited. Conclusion: The medical treatment of complex eyelid BCC is a useful alternative to surgery in the elderly with significant co-morbidities. It provides a promising long-term relief with a tolerable side-effect profile. A prospective, randomized, double-blinded trial would provide stronger evidence for the efficacy of these drugs.

Download Full-text

Side effects of the metacognitive training for depression compared to a cognitive remediation training in patients with depression

Scientific Reports ◽

10.1038/s41598-021-87198-8 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Mona Dietrichkeit ◽

Marion Hagemann-Goebel ◽

Yvonne Nestoriuc ◽

Steffen Moritz ◽

Lena Jelinek

Keyword(s):

Side Effects ◽

Side Effect ◽

Statistical Power ◽

Controlled Trial ◽

Treatment Options ◽

Cognitive Remediation ◽

Negative Effects ◽

Metacognitive Training ◽

To Receive

AbstractAlthough awareness of side effects over the course of psychotherapy is growing, side effects are still not always reported. The purpose of the present study was to examine side effects in a randomized controlled trial comparing Metacognitive Training for Depression (D-MCT) and a cognitive remediation training in patients with depression. 84 patients were randomized to receive either D-MCT or cognitive remediation training (MyBrainTraining) for 8 weeks. Side effects were assessed after the completion of each intervention (post) using the Short Inventory of the Assessment of Negative Effects (SIAN) and again 6 months later (follow-up) using the Negative Effects Questionnaire (NEQ). D-MCT and MyBrainTraining did not differ significantly in the number of side effects. At post assessment, 50% of the D-MCT group and 59% of the MyBrainTraining group reported at least one side effect in the SIAN. The most frequently reported side effect was disappointment in subjective benefit of study treatment. At follow-up, 52% reported at least one side effect related to MyBrainTraining, while 34% reported at least one side effect related to the D-MCT in the NEQ. The most frequently reported side effects fell into the categories of “symptoms” and “quality”. Our NEQ version was missing one item due to a technical error. Also, allegiance effects should be considered. The sample size resulted in low statistical power. The relatively tolerable number of side effects suggests D-MCT and MyBrainTraining are safe and well-received treatment options for people with depression. Future studies should also measure negative effects to corroborate our results.

Download Full-text

Suvorexant: A boon for Sleepless Nights

Medical Journal of Shree Birendra Hospital ◽

10.3126/mjsbh.v14i1.14842 ◽

2016 ◽

Vol 14 (1) ◽

pp. 43-45

Author(s):

Anjan Khadka ◽

Dick Brashier ◽

Amol Vijay Khanpure ◽

Pem Chuki

Keyword(s):

General Practice ◽

Side Effects ◽

Side Effect ◽

Sleep Onset ◽

Side Effect Profile ◽

New Class ◽

Sleep Maintenance ◽

Nonrestorative Sleep ◽

Arousal System ◽

Falling Asleep

Insomnia is characterized by difficulty in falling asleep, difficulty maintaining sleep, or experiencing nonrestorative sleep. Insomnia is the most common medical complaint in general practice. Low efficacy and various side effects limit the use of existing treatment option. Suvorexant is an orexin receptor antagonist (ORA), first in a new class of drugs in development for the treatment of insomnia. It inhibits the wakefulness-promoting orexin neurons of the arousal system thereby promoting the natural transition from wakefulness. It also improves sleep onset and sleep maintenance and has a favorable tolerability and limited side-effect profile.

Download Full-text